J&J: JNJ-5939 WAS WELL TOLERATED IN PHASE 2B DUPLEX-AD PROOF-OF-CONCEPT STUDY
J&J: JNJ-5939 MET PRESPECIFIED CRITERIA FOR EARLY TERMINATION OF THE STUDY
Source text: [ID:]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.